All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2018-07-13T09:00:56.000Z

EHA 2018 | Phase I study of the synergistic effects of CC-122 and obinutuzumab

Jul 13, 2018
Share:

Bookmark this article

On Friday 15th June an oral abstract session took place at the 23rd congress of the European Hematology Association (EHA). Abstract S104 was presented by Jean-Marie Michot, Institute Gustave Roussy, Villejuif, France, on the drug CC-122, which is a novel cereblon-modulating agent used in combination with obinutuzumab in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

CC-122 targets Cereblon and induces degradation of Aiolos and Ikaros that has a dual effect; tumoricidal effects of ISGs (IRF7 and OAS) and T- and NK-cell activation.

Study Overview

  • The initial part of the study was a dose escalation followed by dose expansion
  • The recommended dose for the dose expansion was 3 mg CC-122 + obinutuzumab divided into two cohorts of patients with follicular lymphoma (FL). The FL-1 cohort had R/R CD20+ disease and were lenalidomide-treated. The FL-2 cohort had R/R CD20+ disease and were lenalidomide-naïve
  • The primary endpoint of the study was to assess the safety and tolerability of CC-122 with obinutuzumab. To identify the non-tolerated dose, maximum tolerated dose (MTD), and the recommended phase II dose
  • The secondary endpoints included; preliminary efficacy, overall response rate (ORR) and progression-free survival (PFS)

Key Findings

  • The best ORR:
    • Diffuse large B-cell lymphoma (DLBCL) (n = 19) = 47%
    • FL + MZL (n = 30) = 77%
  • Median PFS:
    • DLBCL = 4.7 months (95% CI, 1.8–13.8)
    • FL + MZL = 16.6 months (95% CI, 5.4–not reached)

Safety

  • The most frequent Grade 3/4 adverse events were neutropenia (55%) and thrombocytopenia (22%)
  • 1 patient had a grade 5 tumor flare reaction/tumor lysis syndrome (dose 4 mg CC-122 + obinutuzumab)

The study found that the recommended dose of CC-122 for future clinical studies was 3 mg with obinutuzumab. This combination demonstrated a high response rate for patients with FL. Additionally, the adverse events during this study were manageable with no unexpected toxicities.

Expert Opinion

  1. Michot JM. CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Abstract S104. 23rd Congress of EHA, Stockholm, Sweden

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 43 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox